Companies developing new cell and tissue-engineered products shouldn’t expect to see much venture funding for their activities at least until the current recession bottoms out and economic growth resumes, according to a US venture capitalist.
Companies developing new cell and tissue-engineered products shouldn’t expect to see much venture funding for their activities at least until the current recession bottoms out and economic growth resumes, according to a US venture capitalist.